J&J's COVID-19 Vaccine On Track To Generate $2.5bn This Year

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The company's pharma revenues grew 17.2% in the second quarter against favorable comparisons and as the COVID-19 pandemic recovery continued.

sales growth
J&J reported strong Q2 financial results • Source: Alamy

Johnson & Johnson expects to generate $2.5bn in revenues from its COVID-19 vaccines in 2021, with more than half the revenues hitting the balance sheet in the fourth quarter, the company reported. J&J incorporated COVID-19 vaccine revenues into its 2021 financial guidance for the first time and updated its financial outlook during the company's second quarter sales and earnings announcement on 21 July.

J&J's one-shot COVID-19 vaccine generated $164m in the second quarter and a total of $264m in the first six months...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.